摘要
目的研究地西他滨联合预激方案治疗急性髓系白血病的临床疗效。方法选取本院2013年1月至2016年1月38例急性髓系白血病患者为研究对象，将纳入患者抽签随机分为观察组和对照组，每组19例。观察组采用地西他滨联合预激方案，对照组采用单纯预激方案，比较两组的临床疗效与不良反应情况。结果观察组的治疗总有效率显著高于对照组（73．7％比42．1％，P〈0．05）。观察组的恶心呕吐、腹泻、脱发、肝功能损伤、肺部感染、血尿、心功能不足发生率分别为26．3％、15．8％、36．8％、15．8％、31．6％、53％、10．5％，与对照组（15．8％、10．5％、26．3％、10．5％、10．5％、0．0％、5.3％）比较差异无统计学意义（P〉0．05）。结论地西他滨联合预激方案治疗急性髓系白血病具有较高的缓解率，同时不会增加过多不良反应，患者耐受性较好，是一种较理想的治疗方案。
Objective To study the clinical effect of decitabine combined with priming chemotherapy in treating acute myelogenous leukemia. Methods Thirty-eight patients with acute myelogenous leukemia admitted in our hospital between January 2013 and January 2016 were selected as study subjects, and randomly divided into the observation group and the control group, 19 cases in each group. The observation group was treated with decitabine combined with priming chemotherapy, while the control group was treated with priming chemotherapy alone. The clinical curative effect and adverse reactions were compared between the two groups. Results The total effective rate in the observation group （73.7%） was higher than that in the control group （42.1%） （P〈0.05）. There were no statistically significant differences in the incidences of nausea and vomiting, diarrhea, hair loss, hepatic injury, pulmonary infection, hematuria, and cardiac insufficiency between the observation group （26.3%, 15.8%, 36.8%, 15.8%, 31.6%, 5.3%, 10.5%） and the control group （15.8%, 10.5%, 26.3%, 10.52%, 10.5%, 0.0%, 5.3%） （P〉0.05）. Conclusion Decitabine combined with priming chemotherapy is with high remission rate in treating acute myelogenous leukemia, and will not increase the incidence of adverse reactions, with good tolerance of patients, which is an ideal treatment method.
出处
《国际医药卫生导报》
2017年第6期846-848,共3页
International Medicine and Health Guidance News
关键词
急性髓系白血病
地西他滨
预激方案
Acute myelogenous leukemia
Decitabine
Priming chemotherapy
